No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Biocon and Janssen Settle Patent Dispute for Ustekinumab with Global Licence
On 29 August 2024, Biocon Ltd announced that it has signed a patent settlement and licence agreement with Janssen which enables Biocon to commercialise Bmab 1200 (ustekinumab), biosimilar to Janssen’s Stelara®, in Europe, the United Kingdom, Canada and Japan. Biocon...